Staff Profile

Positions:

Research Associate - Paediatric Brain Tumour Group, NUTCRI, Newcastle University (2018 to present).

Research Technician - Leukaemia Research Cytogenetics Group, NICR, Newcastle University (2011-2014).

Qualifications:

PhD, Molecular Paediatric Oncology - Newcastle University (2018).

BSc (Hons) Biomedical Sciences - Northumbria University (2011).

Memberships:

British Association for Cancer Research

European Association for Cancer Research

International Society for Paediatric Oncology; SIOPE-Brain Tumour Group

Google Scholar: click here

Teaching:

Genetics and Human Disease (BMS3010) - Seminar leader

Biochemistry (BGM1002) - Seminar leader

MBBS (A100/A101) - Cell cycle, cancer and pathology lecturer

Practical and Presentational Skills in Biomedical Sciences (BMS2013) - Assessor

Supervision:

MRes (Cancer studies); 8 students including 5 intercalating MBBS (2014-current).

BSc (Biomedical Sciences/Human Genetics/Biochemistry); 10 students (2012-current).

MSc (Bioinformatics); 1 student (2020).

• Articles

  • Goddard J, Castle J, Southworth E, Fletcher A, Crosier S, Martin-Guerrero I, Garcia-Ariza M, Navajas A, Masliah-Planchon J, Bourdeaut F, Dufour C, Ayrault O, Goschzik T, Pietsch T, Sill M, Pfister SM, Rutkowski S, Richardson S, Hill RM, Williamson D, Bailey S, Schwalbe EC, Clifford SC, Hicks D. Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification. Acta Neuropathologica 2023, 145, 651–666.
  • Mainwaring OJ, Weishaupt H, Zhao M, Rosen G, Borgenvik A, Breinschmid L, Verbaan AD, Richardson S, Thompson D, Clifford SC, Hill RM, Annusver K, Sundstrom A, Holmberg KO, Kasper M, Hutter S, Swartling FJ. ARF suppression by MYC but not MYCN confers increased malignancy of aggressive pediatric brain tumors. Nature Communications 2023, 14(1), 1221.
  • Williamson D, Schwalbe EC, Hicks D, Aldinger KA, Lindsey JC, Crosier S, Richardson S, Goddard J, Hill RM, Castle J, Grabovska Y, Hacking J, Pizer B, Wharton SB, Jacques TS, Joshi A, Bailey S, Clifford SC. Medulloblastoma group 3 and 4 tumors comprise a clinically and biologically significant expression continuum reflecting human cerebellar development. Cell Reports 2022, 40(5), 111162.
  • Borgenvik A, Holmberg KO, Bolin S, Zhao M, Savov V, Rosen G, Hutter S, Garancher A, Rahmanto AS, Bergstrom T, Olsen TK, Mainwaring OJ, Sattanino D, Verbaan AD, Rusert JM, Sundstrom A, Bravo MB, Dang Y, Wenz AS, Richardson S, Fotaki G, Hill RM, Dubuc AM, Kalushkova A, Remke M, Cancer M, Jernberg-Wiklund H, Giraud G, Chen X, Taylor MD, Sangfelt O, Clifford SC, Schuller U, Wechsler-Reya RJ, Weishaupt H, Swartling FJ. Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma. Cancer Research 2022, 82(24), 4586-4603.
  • Chen Z, Ioris RM, Richardson S, Van Ess AN, Vendrell I, Kessler BM, Buffa FM, Busino L, Clifford SC, Bullock AN, D'Angiolella V. Disease-associated KBTBD4 mutations in medulloblastoma elicit neomorphic ubiquitylation activity to promote CoREST degradation. Cell Death and Differentiation 2022, 29, 1955-1969.
  • Richardson S, Murray J, Davis D, Stephan BCM, Robinson L, Brayne C, Barnes L, Parker S, Sayer A, Dodds R, Allan L. Delirium and delirium severity predict the trajectory of the Hierarchical Assessment of Balance and Mobility (HABAM) in hospitalised older people: findings from the DECIDE Study. The Journals of Gerontology Series A 2022, 77(3), 531-535.
  • Hicks D, Rafiee G, Schwalbe EC, Howell CI, Lindsey JC, Hill RM, Smith AJ, Adidharma P, Steel C, Richardson S, Pease L, Danilenko M, Crosier S, Joshi A, Wharton SB, Jacques TS, Pizer B, Michalski A, Williamson D, Bailey S, Clifford SC. The molecular landscape and associated clinical experience in infant medulloblastoma: prognostic significance of second-generation subtypes. Neuropathology and Applied Neurobiology 2021, 47(2), 236-250.
  • Dodds RM, Murray JC, Granic A, Hurst C, Uwimpuhwe G, Richardson S, Brayne C, Matthews FE, Sayer AA, CFAS MRC. Prevalence and factors associated with poor performance in the 5-chair stand test: findings from the Cognitive Function and Ageing Study II (CFAS II) and proposed Newcastle protocol for use in the assessment of sarcopenia. Journal of Cachexia, Sarcopenia and Muscle 2021, 12(2), 308-318.
  • Hill RM, Richardson S, Schwalbe EC, Hicks D, Lindsey JC, Crosier S, Rafiee G, Grabovska Y, Wharton SB, Jacques TS, Michalski A, Joshi A, Pizer B, Williamson D, Bailey S, Clifford SC. Time, pattern, and outcome of medulloblastoma relapse and their association with tumour biology at diagnosis and therapy: a multicentre cohort study. The Lancet Child and Adolescent Health 2020, 4(12), 865-874.
  • Ryan SL, Matheson E, Grossmann V, Sinclair P, Bashton M, Schwab C, Towers W, Partington M, Elliott A, Minto L, Richardson S, Rahman T, Keavney B, Skinner R, Bown N, Haferlach T, Vandenberghe P, Haferlach C, Santibanez-Koref M, Moorman AV, Kohlmann A, Irving JA, Harrison CJ. The role of the RAS pathway in iAMP21-ALL. Leukemia 2016, 30, 1824-1831.
  • Schwab C, Ryan SL, Chilton L, Elliott A, Murray J, Richardson S, Wragg C, Moppett J, Cummins M, Tunstall O, Parker CA, Saha V, Goulden N, Vora A, Moorman AV, Harrison CJ. EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications. Blood 2016, 127(18), 2214-2218.
  • Moorman AV, Enshaei A, Schwab C, Wade R, Chilton L, Elliott A, Richardson S, Hancock J, Kinsey SE, Mitchell CD, Goulden N, Vora A, Harrison CJ. A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia. Blood 2014, 124(9), 1434-1444.

• Conference Proceedings (inc. Abstracts)

  • Goddard J, Castle J, Southworth E, Fletcher A, Crosier S, Martin-Guerrero I, Garcia-Ariza M, Navajas A, Masliah-Planchon J, Bourdeaut F, Dufour C, Goschizk T, Pietsch T, Richardson S, Hill R, Williamson D, Bailey S, Schwalbe E, Clifford S, Hicks D. MEDB-71. Molecular characterisation of Group 4 medulloblastoma improves risk-stratification and its biological understanding. In: 20th International Symposium on Pediatric Neuro-Oncology (ISPNO 2022). 2022, Hamburg, Germany: Oxford University Press.
  • Schwab C, Andrews R, Chilton L, Elliott A, Richardson S, Ryan SL, Logan A, Fielding AK, Goulden N, Vora AJ, Moorman AV, Macartney CA, Harrison CJ. SSBP2-CSF1R Is a Recurrent Fusion in B-Other Acute Lymphoblastic Leukaemia with Variable Clinical Outcome. In: 56th ASH Annual Meeting and Exposition. 2014, San Francisco, California: American Society of Hematology.
  • Schwab C, Andrews R, Chilton L, Elliott A, Keil G, Richardson S, Ryan SL, Wragg C, Moppett J, Cummins M, Goulden N, Vora AJ, Moorman AV, Harrison CJ. EBF1-PDGFRB Fusion in Paediatric Acute Lymphoblastic Leukaemia (ALL): Genetic Profile and Clinical Implications. In: 56th ASH Annual Meeting and Exposition. 2014, San Francisco, California: American Society of Hematology.